Comparative Study of Nedaplatin or Irinotecan Combined with Paclitaxel for Interim or Advanced Cervical Cancer

Objective To compare the efficacy of nedaplatin or irinotecan combined with paclitaxel as first choice for interim or advanced cervical cancer.Methods 90 patients with interim or advanced cervical cancer received different chemotherapy regimens for treatment.The control group were treated with nedaplatin combined with paclitaxel,the observation group were treated with irinotecan and paclitaxel.Short-term efficacy,long-term efficacy,adverse reactions and long-term survival rates were compared.Results Effective rate of the observation group was 75.56%,significantly higher than 51.11% in the control group(P0.05).The 1-year,3-year survival rates were 71.11%,55.56% in the observation group,higher than 55.56%,31.11% in the control group,(P0.05).In addition,the 2 groups had adverse reactions in varied degrees.Gastrointestinal discomfort of the observation group were significantly less than that of the control group(P0.05).Conclusion Irinotecan combined with paclitaxel is an effective treatment for interim or advanced cervical cancer with fewer adverse reactions,and can significantly improve long-term survival rates of patients.It is worthy of further clinical application.